Defining how extra-lymphoid tissue regulates sex differences in the immune response
Defining how extra-lymphoid tissue regulates sex differences in the immune response
Funding Agency: W.M. Keck Foundation


Role on Project: Principal Investigator


Budget Period: 07/01/2019 – 06/30/22


Total Funding: $ 1,000,000


It is well-known that males and females exhibit different immune responses with females responding more robustly in nearly all cases. The reasons for this difference are not entirely understood. We found that males and females appear to have evolved the ability to trigger immunity differently in traditional (lymphoid) and non-traditional (non-lymphoid) organs throughout the body. To help decipher these responses, we propose to investigate how immune cells in these organs are differentially activated by a variety of challenges and how hormones and sex chromosomes regulate the unique differences of immune cells in these distinctive tissues.

Read More
Using combination adjuvants to direct and control immune responses at the intestinal mucosa
Using combination adjuvants to direct and control immune responses at the intestinal mucosa
Funding Agency: NIH/NIAID


Role on Project: Principal Investigator


Budget Period: 04/01/2017 – 03/31/2021


Total Funding: $2,069,315


Vaccines are one of the most important medical interventions in history, yet every year nearly 15 million people die worldwide from infectious diseases. Often this is associated with intestinal pathogens. This highlights the need for new and efficacious vaccines. The goal of the proposed research is to understand how adjuvant combinations can be used to target multiple aspects of immunity to the intestinal mucosal and how this might be "tuned" to target particular pathogens. As such, the proposed research is relevant to the part of the NIH's mission that pertains to developing fundamental knowledge to reduce the burdens of human disease.

Read More
Development of outer membrane vesicles as a novel adjuvant
Development of outer membrane vesicles as a novel adjuvant
Funding Agency: NIH/NIAID


Role on Project: Co-Principal Investigator


Budget Period: 09/30/2018 – 09/29/2023


Total Funding: $ 8,500,000


The goal of this study is to develop a more effective and longer-lasting vaccine against pertussis, more commonly known as “whooping cough.” We will add bacterial outer membrane vesicles to DTaP, an existing vaccine against three deadly diseases caused by bacteria: diphtheria, tetanus and pertussis. We'll use this to evaluate the OMV-based vaccine’s safety and effectiveness in animal models paving the way for potential clinical studies.

Read More

Completed Funding

Copyright ©McLachlan Lab 2020

Twitter: @McLachlanLab